Search This Blog

Wednesday, June 28, 2023

ImmuCell: Anticipated FDA Submission Delayed

  ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule.

“Although we had planned to make our next FDA submission during the second quarter of this year, we have decided to add one additional month to the projected regulatory development process for Re-Tain®,” commented Michael F. Brigham, President and CEO of ImmuCell. “The CMC Technical Section is ready for submission at this time, but we are going to use this extra time to optimize our readiness for the related pre-approval re-inspection.”

https://finance.yahoo.com/news/immucell-announces-change-timing-anticipated-200500106.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.